PharmaEngine’s third-quarter profits reached the highest level of the year, with earnings per share for the first three quarters standing at NT$1.79. The company is scheduled to hold an online investor conference this afternoon, where attention is expected to focus on the clinical development of its proprietary anti-cancer drugs, including PEP07, which is expected to confirm its maximum tolerated dose by year-end, and PEP08, which has already entered Phase I human clinical trials.

PharmaEngine is shifting its new drug development focus toward proprietary products. The two selected anti-cancer candidates target areas of high market interest. PEP07 is an oral small-molecule CHK1 inhibitor that acts on the DNA damage response pathway. Compared to other competitors, it offers high selectivity and the ability to cross the blood-brain barrier. Phase I trials are currently ongoing for both hematologic and solid tumors, with maximum tolerated dose expected to be determined by the end of the year.

PEP08 is a PRMT5 inhibitor, a leading candidate in the global oncology targeted therapy field. Its Phase I trial has already enrolled the first patient and begun dosing. The study plans to recruit 40 cancer patients across Taiwan and Australia, with completion expected within two years.

Resource: 智擎Q3獲利衝今年高，自研抗腫瘤新品陸續推進臨床